Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group

Trillsch, Fabian; Mahner, Sven; Czogalla, Bastian; Rottmann, Miriam; Chekerov, Radoslav; Braicu, Elena; Oskay-Oczelik, Gulten; Wimberger, Pauline; Richter, Rolf; Sehouli, Jalid

doi:10.3802/jgo.2021.32.e37

Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group

Trillsch F., Mahner S., Czogalla B., Rottmann M., Chekerov R., Braicu E. I., ...Daha Fazla

JOURNAL OF GYNECOLOGIC ONCOLOGY, cilt.32, sa.3, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 32 Sayı: 3
Basım Tarihi: 2021
Doi Numarası: 10.3802/jgo.2021.32.e37
Dergi Adı: JOURNAL OF GYNECOLOGIC ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE
Anahtar Kelimeler: Recurrent Ovarian Cancer, Primary Platinum Resistance, Mono-chemotherapy, Anti-angiogenic Treatment, Sorafenib, Prognostic Factor
Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Objective: Patients with platinum-resistant ovarian cancer (PROC) have a high need for reliable prognostic markers. Since significance of primary platinum resistance (PPR) versus secondary platinum resistance (SPR) was identified for patients receiving anti-angiogenic therapy, it has not been confirmed for chemotherapy only.